What type of study is this?

This is a Literature Review study.

September 10, 2025Open Access

Analysis of the Structural Diversity of Heterocycles amongst European Medicines Agency Approved Pharmaceuticals (2014–2023)

Key Points

The diversity of heterocycles is significant in new active substances approved by the EMA.
This analysis spans medicines approved from 2014 to 2023, showcasing structural variation.
Heterocycles contribute greatly to the complexity of pharmaceutical compounds in this period.
Understanding heterocycle diversity aids in the development of innovative pharmaceuticals.

Abstract

This review presents a detailed analysis of the heterocycle diversity amongst medicines with new active substances (NAS) approved by the European Medicines Agency in the last 10 years (2014–2023). A...

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Ward et al. (Wed,) studied this question.

synapsesocial.com/papers/68c1c31254b1d3bfb60f051f — DOI: https://doi.org/10.1039/d5md00403a

Authors

Matthew Ward

Trinity College

Niamh M. O’Boyle

Trinity College Dublin

Journals

RSC Medicinal Chemistry

Actions

Institutions

Trinity College Dublin

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Analysis of the Structural Diversity of Heterocycles amongst European Medicines Agency Approved Pharmaceuticals (2014–2023)

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion